41O Stock Chart & Stats
€0.22
-€0.10(-4.39%)
At close: 4:00 PM EST
€0.22
-€0.10(-4.39%)
Day’s Range― - ―
52-Week Range€0.15 - €2.80
Previous CloseN/A
Volume0.00
Average Volume (3M)5.40K
Market Cap
€230.95M
Enterprise Value€36.28
Total Cash (Recent Filing)€7.75M
Total Debt (Recent Filing)€27.19M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 13, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding186,997,000
10 Day Avg. Volume4,894
30 Day Avg. Volume5,396
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.15
Price to Sales (P/S)26.09
P/FCF Ratio-0.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.10Price Target Upside2217.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.42
Revenue Forecast (FY)€12.44M
Bulls Say, Bears Say
Bulls Say
FDA BLA Acceptance (Class 1)The FDA's Class 1 acceptance and a defined PDUFA goal date materially shorten regulatory uncertainty timing. If approved, the company could transition from development to commercial execution, enabling product revenues and validating the core business model in the ophthalmic biologics market.
Successful FDA AppealWinning the Formal Dispute Resolution reduces clinical-regulatory risk by confirming trial data suffices, avoiding new large trials. This preserves development capital, accelerates potential market entry, and strengthens the company's ability to realize value from its ONS-5010 program over the coming months.
Regained Nasdaq ComplianceRestoring listing compliance removes delisting risk and maintains liquidity and market access. This preserves the company's ability to tap public equity, retain institutional investors, and pursue follow-on financings needed to fund commercialization if regulatory approval is achieved.
Bears Say
Negative Shareholder EquityPersistently negative shareholder equity indicates accumulated losses have overwhelmed the capital base, weakening financial flexibility. This structural weakness constrains borrowing capacity, complicates strategic partnerships, and increases the probability of further equity-based dilution to sustain operations.
Consistent Cash BurnOngoing negative operating and free cash flow demonstrate the business is not self-funding and must rely on external capital. Over months, this elevates execution risk for commercialization and commercialization support activities and forces management to prioritize financing over long-term investments.
Heavy Reliance On Equity FinancingBroad shareholder approvals to materially expand authorized shares, alongside recent registered direct offerings and an ATM, signal structural dependence on dilutive equity financing. That reliance raises medium-term dilution risk and may pressure management to issue shares rather than pursue non-dilutive funding.
Outlook Therapeutics News
41O FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was €0.15 and its highest was €2.80 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is €230.95M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 18 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on May 15, 2026. The company reported -€0.141 earnings per share for the quarter, missing the consensus estimate of -€0.106 by -€0.034.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 186,997,000 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -€0.141 in its last earnings report, missing expectations of -€0.106. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in DE:41O
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outlook Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.10 (2217.52% Upside)
€5.10 (2217.52% Upside)
Blogger Sentiment
Bullish
DE:41O Sentiment 70%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth €4.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.77%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
41O Stock 12 Month Forecast
Average Price Target
€5.10
▲(2217.52% Upside)
Technical Analysis
Oramed Pharm
―
Atara Biotherapeutics
―
Whitehawk Therapeutics
―
Celularity
―
Adagene
―